Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Phase 3

Hyaluronic Acid Injection in Idiopathic Carpal Tunnel Syndrome; is it Effective as Local Corticosteroids

NCT07474714 · tracked via the Priya Life Science Egypt tracker
Phase
Phase 3
Started
2026-02
Last updated
2026-03-17

Condition(s) studied

Carpal Tunnel Syndrome (CTS)

Investigational drug(s) / intervention(s)

Low Molecular Weight Hyaluronic Acidcorticosteroid

Low Molecular Weight Hyaluronic Acid: Ultrasound-guided perineural injection of low molecular weight Hyaluronic Acid.

corticosteroid: Ultrasound-guided perineural injection of corticosteroids

Study summary

This study compares the effectiveness of two types of local injections-Hyaluronic Acid (HA) and corticosteroids-for treating mild to moderate idiopathic Carpal Tunnel Syndrome (CTS). Sixty adult patients will be assigned to receive one of the two injections under ultrasound guidance. The goal is to see if HA is as effective as the standard corticosteroid treatment in improving symptoms and nerve function over a 3-month follow-up period.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Numbness or pain in the Median Nerve (MN) distribution. 2. Nerve conduction studies (NCS) consistent with CTS as per the AANEM guidelines. 3. An MN cross-sectional area (CSA) at the wrist \>12 mm² Exclusion Criteria: 1. Patients with severe symptoms (indication for surgery). 2. Patients who show improvement on medical treatment. 3. Patients with previous surgical or injectional CTS treatment. 4. Coexistence of brachial plexopathy, or thoracic outlet syndrome. 5. Patients with infection at the site of injection.

Primary outcome measure(s)

  • Change in Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) Scores — Baseline, 1 month, and 3 months post-injection
    Comparison of the BCTQ scores (symptom severity and functional status) between the Hyaluronic Acid and Corticosteroid groups.
  • Change in Electro-diagnostic Parameters — Time Frame Baseline, 1 month, and 3 months post-injection
    Comparison of sensory and motor electrodiagnostic parameters between the two groups, including peak sensory latency (ms), sensory nerve action potential - SNAP (µV), sensory conduction velocity - SCV (m/s), distal motor latency (ms), compound muscle action potential - CMAP (mV), and motor conduction velocity - MCV (m/s).
  • Change in Neuromuscular Ultrasound Examination Parameters — Baseline, 1 month, and 3 months post-injection
    Comparison of neuromuscular ultrasound parameters between the two groups, including the median nerve cross-sectional area (CSA) measured in mm², fascicular pattern, flattening ratio, and mobility of the median nerve.

Trial sites (1)

FacilityCityRegionStatus
Minia University Hosopital Minya Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07474714 on ClinicalTrials.gov ↗ ← All trials in Egypt